September 7, 2015

Verseon Corporation (“Verseon” or the “Company”)

Interim Results

Verseon (AIM:VSN), a technology-based pharmaceutical company, today announces its Interim Results for the half-year ended 30 June 2015.

Financial and Operational Highlights

  • Raised US $100.0 million before expenses through an initial public offering (IPO) by placing 32.6 million shares of common stock on the Alternative Investment Market (AIM) of the London Stock Exchange.
  • Cash and cash equivalents as of June 30, 2015 was US $93.6 million.
  • Operating expenses for the first six months of 2015 were $3.6 million, but partially offset by a currency gain of $3.0 million. The resultant net loss for the first six months of 2015 was $0.6 million, or $0.005 per share, compared to a net loss of $2.1 million, or $0.082 per share, for the same period in 2014.
  • The Company continues to advance its three drug programs in anti-coagulation, treatment of diabetic macular edema and treatment of solid tumor cancers, while building infrastructure to support further growth of its drug pipeline.
  • In August 2015, the Company purchased a property through its wholly owned subsidiary, VRH1 LLC, for $8.7 million. This acquisition will facilitate the Company’s planned expansion of its drug discovery and development operations.

For further information

VerseonTel: +1 (510) 225 9000
Adityo Prakash, Chief Executive
Cenkos (NOMAD & Broker)
Christopher Golden / Mark ConnellyTel: +44 (0) 20 7 397 8900

Financial and Business media enquiries

Abchurch Communications Limited
Jamie Hooper / Viktoria Langley / Alex ShawTel: +44 (0) 20 7398 7719

Trade and pharma media enquiries

Vane Percy RobertsTel: +44 (0) 1737 821 890
Simon Vane Percy

Notes to editors

Verseon is a pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. The Company is applying its platform to a growing drug pipeline and has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.

For more information, please visit:

Download additional details (320k)

Proprietary Platform

Consistently designs novel drug candidates that are unlikely to be found using conventional methods


Drug Programs

Multiple therapeutic areas, all with unmet (or poorly met) medical needs